Internal Medicine, Infectious Disease · Jackson, MI
NPI
1821009655
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1100 E Michigan Ave, Suite 305
Jackson, MI, 49201
Phone (517) 788-4781
Groups this clinician bills Medicare through
Medicare paid, 2024
$609K
171,750 services
Medicare patients, 2024
450
Average age 72
Drug cost, 2024
$1.1M
957 prescriptions
Company payments, 2025
$43.8
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vivek Kak was code J0878 (injection, daptomycin, 1 mg), 94,600 times for 31 patients. In total Vivek Kak billed 171,750 services in 93 codes, and Medicare paid $609K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0878 Injection, daptomycin, 1 mg | Office | 94,600 | 31 | $0.05 | $5,181 |
| J0872 Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg | Office | 37,000 | 13 | $0.25 | $9,160 |
| J0875 Injection, dalbavancin, 5 mg | Office | 3,800 | 12 | $11.99 | $46K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 3,160 | 19 | $36.42 | $115K |
| J0696 Injection, ceftriaxone sodium, per 250 mg | Office | 2,136 | 32 | $0.35 | $753 |
| 96365 Intravenous Infusion, Hydration | Office | 658 | 131 | $42.83 | $28K |
| J0561 Injection, penicillin g benzathine, 100,000 units | Office | 516 | 11 | $18.01 | $9,295 |
| 99213 Office E&M - Established | Office | 269 | 144 | $63.65 | $17K |
| 96367 Intravenous Infusion, Hydration | Office | 234 | 51 | $19.97 | $4,673 |
| 96366 Intravenous Infusion, Hydration | Office | 219 | 32 | $13.98 | $3,061 |
| 99222 Hospital E&M - Initial | Facility | 170 | 166 | $101.30 | $17K |
| 99214 Office E&M - Established | Office | 143 | 94 | $90.49 | $13K |
| J1335 Injection, ertapenem sodium, 500 mg | Office | 131 | 16 | $8.81 | $1,155 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 71 | 45 | $11.96 | $849 |
| 96372 Injection Administration | Office | 65 | 20 | $9.72 | $632 |
By year: 2022 $628K for 159,882 services; 2023 $758K for 188,647 services; 2024 $609K for 171,750 services.
Medicare prescription drug claims, 2024
In 2024, the drug Vivek Kak prescribed most often to Medicare patients was Doxycycline Hyclate, with 64 prescriptions and refills. In total Vivek Kak wrote 957 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Doxycycline Hyclate Generic | 64 | 83 | 35 | $696 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 62 | 84 | 24 | $305 |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 40 | 40 | Under 11 | $150K |
| Minocycline Hcl Generic | 39 | 41 | 17 | $1,500 |
| Vancomycin Hcl Generic | 37 | 39 | 16 | $4,896 |
| Ciprofloxacin Hcl Generic | 36 | 38 | 22 | $311 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 34 | 34 | 26 | $352 |
| Cephalexin Generic | 34 | 52 | 20 | $754 |
| Methenamine Hippurate Generic | 33 | 35 | Under 11 | $2,588 |
| Cefuroxime Cefuroxime Axetil | 31 | 31 | 24 | $470 |
| Juluca Dolutegravir/Rilpivirine | 30 | 30 | Under 11 | $107K |
| Azithromycin Generic | 29 | 49 | 11 | $429 |
| Rifampin Generic | 27 | 37 | 11 | $1,693 |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 25 | 25 | Under 11 | $96K |
| Prednisone Generic | 23 | 24 | 14 | $84.75 |
Brand drugs: - claims; generic drugs: 738 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vivek Kak $43.8 ($43.8 in general payments such as food, travel and fees) from 2 companies. The largest payer was Merck Sharp & Dohme LLC with $25.7.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 1 | $25.7 |
| Aimmune Therapeutics, Inc. | 1 | $18.1 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.